Actionable news
0
All posts from Actionable news
Actionable news in INCY: Incyte Corporation,

5 Immunotherapy Stocks to Watch for Treating Cancer

Interest in immunotherapies continues to build up - earlier this week, Loncar Cancer Immunotherapy ETF CNCR, the first ETF dedicated only to stocks involved in the research and development of immuno-oncology treatments, started trading on NASDAQ.

The Loncar Cancer Immunotherapy ETF comprises both large pharma and growth-oriented biotech companies working on immuno-oncology treatments.

Understanding Immuno-Oncology

The basic concept of cancer immunotherapy or immuno-oncology is to utilize certain parts of the immune system to fight the disease. This can be done by stimulating the immune system to attack cancer cells or by introducing immune system components into the body. While some immuno-oncology treatments have the potential to be effective as monotherapies, others may be more effective when combined with other treatments.

Different types of immunotherapies include monoclonal antibodies/mAbs (man-made versions of immune system proteins which can be designed to attack a very specific part of a cancer cell), immune checkpoint inhibitors (recognize and attack cancer cells), vaccines (help prevent or treat cancer) and others that boost the overall immune system.

Encouraging results generated by some companies demonstrating partial and complete responses in late-stage cancer patients has raised hopes for cancer patients and increased interest in the investor community.

5 Promising Immuno-Oncology Focused Stocks

Given the growing interest in immuno-oncology treatments, let’s take a look at some pharma and biotech companies that are looking to change the way we treat cancer.

First on the list is Amgen AMGN, one of the biggest and most well-known names in...


More